Premium
Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study
Author(s) -
Altomare Daniele,
Collij Lyduine,
Caprioglio Camilla,
Scheltens Philip,
Berckel Bart N.M.,
Alves Isadora Lopes,
Berkhof Johannes,
Gier Yvonne,
Garibotto Valentina,
Moro Christian,
Poitrine Léa,
Delrieu Julien,
Payoux Pierre,
SaintAubert Laure,
Molinuevo José Luis,
GrauRivera Oriol,
Gispert JuanDomingo,
Minguillón Carolina,
Fauria Karine,
Sanchez Marta Felez,
Rădoi Andreea,
Drzezga Alexander,
Jessen Frank,
Escher Claus,
Zeyen Philip,
Nordberg Agneta,
Savitcheva Irina,
Jelic Vesna,
Walker Zuzana,
Lee HoYun,
Lee Lean,
Demonet JeanFrançois,
Plaza Wuthrich Sonia,
Gismondi Rossella,
Farrar Gill,
Barkhof Frederik,
Stephens Andrew W.,
Frisoni Giovanni B.
Publication year - 2023
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12696
Subject(s) - memory clinic , generalizability theory , dementia , medicine , cohort , representativeness heuristic , population , cohort study , randomized controlled trial , cognition , psychiatry , psychology , disease , developmental psychology , social psychology , environmental health
AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost‐effectiveness of amyloid‐PET in Europe. Here we present participants’ baseline features and discuss the representativeness of the cohort. Methods Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid‐PET; ARM2, late amyloid‐PET; and ARM3, free‐choice. Results A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms. Discussion The features of AMYPAD‐DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.